BiotechTube
Home/Pipeline/Cancer Immunotherapy Nanotherapeutic

Cancer Immunotherapy Nanotherapeutic

Oncology (unspecified)

Phase 1Active

Key Facts

Indication
Oncology (unspecified)
Phase
Phase 1
Status
Active
Company
Flashpoint Therapeutics

About Flashpoint Therapeutics

Flashpoint Therapeutics is a private, clinical-stage biotech leveraging a nanotechnology platform pioneered in Chad Mirkin's lab to create targeted, multi-component nanomedicines. Its platform, validated in vivo and with an IND-cleared candidate, demonstrates significant improvements in potency, delivery, and stability across various therapeutic modalities, including cancer immunotherapy. The company is advancing an internal pipeline while seeking strategic partnerships to develop best-in-class RNA and peptide therapeutics.

View full company profile

Therapeutic Areas

OncologyGenetic DiseasesNeurological Disorders

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a
DDX3 Inhibitor (Oncology)Lead Discovery SienaDiscovery